Targeting the p75 Receptor to Inhibit Degenerative Signaling and Tau Phosphorylation/Misfolding/ Missorting: Preclinical through Phase 1
|
|
- Emory Baker
- 5 years ago
- Views:
Transcription
1 Targeting the p75 Receptor to Inhibit Degenerative Signaling and Tau Phosphorylation/Misfolding/ Missorting: Preclinical through Phase 1 ADC Directors Meeting, April 18 th 2015 Frank M. Longo, Stanford University UNC/UCSF Stanford Also: Steve Massa, MD, PhD at UCSF Academic/mechanistic studies ADDF Alzheimer s Association NIA U01 NINDS R21 Taube Family Koret Fdn Jean Perkins Fdn Horngren Family
2 Other factors: age, inflammation amyloid receptors Ca 2+ /Ox mito membrane effects Rho A PKA calpain MLK p-cofilin p-creb cdk5 p38 GSK3β JNK AKT p-tau / mf-tau / tau-o / ml-tau p-fyn Synaptic dysfunction Spine loss Neurite degeneration p-nr2b
3 Other factors: age, inflammation amyloid prongf/ngf p75 receptors Ca 2+ /Ox mito membrane effects Rho/GDI Death adaptors Survival adaptors Rho A PKA calpain MLK PI3K p-cofilin p-creb cdk5 p38 GSK3β JNK AKT p-tau / mf-tau / tau-o / ml-tau p-fyn Synaptic dysfunction Spine loss Neurite degeneration p-nr2b
4 Other factors: age, inflammation amyloid p75 receptors Ca 2+ /Ox mito membrane effects Rho/GDI Death adaptors Survival adaptors Rho A PKA calpain MLK PI3K p-cofilin p-creb cdk5 p38 GSK3β JNK AKT p-tau / mf-tau / tau-o / ml-tau p-fyn Synaptic dysfunction Spine loss Neurite degeneration p-nr2b
5 Aβ-induced degeneration is p75 dependent oligomeric-aβ + 21 div HC neurons p75+/+ p75+/+ dystrophic neurites (APP IHC) APP-L/S X p75 -/- p75-/- P75-/- mean differential angle CM *** *** CM Aβ1-42 Aβ1-42 p75 +/+ p75 -/- p75 enables Aβ-induced degeneration Knowles et al, J Neurosci 2009 Coulson Lab 2009 Bartlett Lab 2015
6 Other factors: age, inflammation amyloid prongf/ngf p75 receptors Ca 2+ /Ox mito membrane effects Rho/GDI Death adaptors Survival adaptors Rho A PKA calpain MLK PI3K p-cofilin p-creb cdk5 p38 GSK3β JNK AKT p-tau / mf-tau / tau-o / ml-tau p-fyn Synaptic dysfunction Spine loss Neurite degeneration p-nr2b
7 Signaling effects: Other factors: age, inflammation amyloid p75 receptors Ca 2+ /Ox mito membrane effects Rho/GDI Death adaptors Survival adaptors Rho A PKA calpain MLK PI3K p-cofilin p-creb cdk5 p38 GSK3β JNK AKT p-tau / mf-tau / tau-o / ml-tau p-fyn Synaptic dysfunction Spine loss Neurite degeneration p-nr2b
8 Signaling effects: Other factors: age, inflammation amyloid p75 Massa et al J Neurosci 2006 receptors Ca 2+ /Ox mito membrane effects Rho/GDI Death adaptors Survival adaptors Rho A PKA calpain MLK PI3K p-cofilin p-creb cdk5 p38 GSK3β JNK AKT p-tau / mf-tau / tau-o / ml-tau p-fyn Synaptic dysfunction Spine loss Neurite degeneration p-nr2b
9 LM11A-31 inhibits Aβ-induced dystrophy CM Aβ 1-42 Aβ ligand (100 nm) E17 div 21 matured hippocampal neurons % of neurites CM Aβ + C Aβ Modified from Yang et al PLoS One, 2008
10 Signaling effects: Other factors: age, inflammation amyloid p75 receptors Ca 2+ /Ox mito membrane effects Rho/GDI Death adaptors Survival adaptors Rho A PKA calpain MLK PI3K p-cofilin p-creb cdk5 p38 GSK3β JNK AKT p-tau / mf-tau / tau-o / ml-tau p-fyn Synaptic dysfunction Spine loss Neurite degeneration p-nr2b
11 Signaling effects: Other factors: age, inflammation amyloid p75 receptors Ca 2+ /Ox mito membrane effects Rho/GDI Death adaptors Survival adaptors Rho A PKA calpain MLK PI3K p-cofilin p-creb cdk5 p38 GSK3β JNK AKT p-tau / mf-tau / tau-o / ml-tau p-fyn Synaptic dysfunction Spine loss Neurite degeneration p-nr2b Yang et al PLoS One 2008 Nguyen et al, JAD 2014 Yang et al, SNS 2014
12 p75 NTR ligands block Aβ-induced p-tau / AT8 epitope Aβ AT8 p-tau Ser202 tau p-tau 202 / tau *** *** *** *** E17 div 21 hippocampal neurons Aβ 1-42 (5μM) Modified from Yang et al PLoS One, 2008
13 Inhibition of Aβ-induced tau mislocalization E17 DIV 21 hippocampal neurons CM Aβ Aβ + C31 (100 nm) MAP2 (dendrites) Tau (axons) ** yellow µm / 100 µm ** FYN-NR2B activation? CM Aβ Aβ + C31 (100 nm) Yang, Longo SNS 2014
14 Inhibition of Aβ-induced FYN and NR2B activation 21 DIV HC neurons p-fyn: CM Aβ Aβ + LM11A-31 p-fyn intensity / neuron (% control) Yang, Longo SNS 2014
15 Inhibition of Aβ-induced FYN and NR2B activation 21 DIV HC neurons p-fyn: CM Aβ Aβ + LM11A-31 p-fyn intensity / neuron (% control) p-nr2b: CM Aβ Aβ + LM11A-31 p-nr2b intensity / neuron (% control) ** ** Yang, Longo SNS 2014
16 Inhibition of Aβ-induced FYN and NR2B activation 21 DIV HC neurons p-fyn: CM Aβ Aβ + LM11A-31 p-fyn intensity / neuron (% control) p-nr2b: CM Aβ Aβ + LM11A-31 p-nr2b intensity / neuron (% control) ** ** LTP/behavior? Yang, Longo SNS 2014
17 In vivo Studies Orally bioavailable CNS Water soluble, stable Brain/plasma > 1 Brain T1/2 ~ 1 hr FDA limit dose 2000 mg/kg non-toxic AMES / herg / CYP each clear ADMET favorable CNS target engagement: p75 cleavage
18 Reduced tau phosphorylation (AT8) APP L/S mice; 50 mg/kg po qd X 3 mo Mo: p-tau Ser 202 (AT8) ctx WT veh WT L Intraneuronal p-tau Tg veh Tg L WT-V WT-L Tg-V Tg-L Nguyen et al, JAD 2014
19 Reduced tau aberrant folding (MC-1) APP L/S mice; 50 mg/kg po qd X 3 mo Mo: L ctx: Nguyen et al JAD 2014
20 Reduction of cortex ChAT neurite loss APP L/S mice; 50 mg/kg po qd X 3 mo Mo: WT veh WT-L Tg veh Tg-L WT-V WT-L Tg-V Tg-L Nguyen et al JAD 2014
21 Reduced loss of LC noradrenergic projection fibers to prefrontal ctx APP L/S mice; 50 mg/kg po qd X 3 mo Mo: TH IHC WT-V WT-L Tg-V Tg-L Nguyen, Longo
22 p75 NTR ligands: LTP and behavior APP-L/S mice 3 mo rx: fepsp slope (% of baseline) Time (min) Ottavio Arancio Lab, Columbia HC slice preparations wt-veh wt-c31 APP/PS1-veh APP/PS1-C31 NOR CFC Y-maze DMP-MWM Knowles et al Neurobiol Aging 2013 Nguyen et al JAD 2014
23 Late stage reversal of BF neurite degeneration APP L/S mice; 50 mg/kg po qd X 1 mo Mo: baseline degen rx W TgV TgL Simmons et al PLoS One 2014
24 Spines: late stage rx with p75 NTR ligands APP L/S mice; 50 mg/kg po qd X 1 mo Mo: Golgi staining HC pyramidal L WT V T41 V T41 L WT V T41 V T41 L Simmons, Longo
25 Microglial activation? Other factors: age, inflammation amyloid p75 receptors Ca 2+ /Ox mito membrane effects Rho/GDI Death adaptors Survival adaptors Rho A PKA calpain MLK PI3K p-cofilin p-creb cdk5 p38 GSK3β JNK AKT p-tau / mf-tau / tau-o / ml-tau p-fyn Synaptic dysfunction Spine loss Neurite degeneration p-nr2b
26 Reduction of microglial activation APP L/S mice; 50 mg/kg po qd X 3 mo Mo: Aberrantly folded tau MG activation Zilka et al J Neuroinflammation, 2012 WT veh WT 31 L Cortex Hippocampus Tg veh Tg 31 L L L L L CD68 IHC PET imaging? Nguyen et al JAD 2014
27 Aged WT mice: reversal of BFCN atrophy 50 mg/kg qd X 4 mo Mo: ChAT IHC MS+VDB 200 p=0.001 p=0.012 ChAT Cell Area mo 25 mo V 25 mo L V 25L 18 mo Xie, Meeker, Longo UNC-CH
28 Challenge of mouse to human prediction Our strategies: Many AD-relevant mechanisms Many in vivo endpoints: morphology, behavior Multiple AD models: APP-L/S (morphology, behavior, mechanisms) Ts65Dn (morphology, behavior) Tg2576 (morphology) PS1-APP(LTP) Effects in aged wild-type mice Reversal of late-stage effects Translatable biomarkers: PET 5 models
29 Phase 1: LM11A-31-M Safety and Pharmacokinetics Single ascending dose (SAD), 6 cohorts: Young subjects: D1-4 dose ascending Elderly: D4 (fasted and non-fasted) 48 subjects (36 drug / 12 placebo) Multiple ascending dose (MAD 10 days), 2 cohorts: Elderly D5 2x/day Elderly D6 1x/day 20 subjects (16 drug / 4 placebo) No serious Adverse Events (AEs) Total: 68 subjects (52 drug / 16 placebo) LM11A-31-M is safe and well tolerated in the target elderly population PharmatrophiX
30 PET/MRI Imaging TSPO ligand: GE-180 Michelle James & Sam Gambhir, Stanford
31 GE-180 PET: APP-L/S mice; 3 mo rx (start mo) wt-vehicle APP L/S -vehicle wt-c31 APP L/S -C31 10 ctx: %ID/g HC: 0 normalized PET signal Cortex *** * normalized PET signal Hippocampus ** * James et al Longo-Gambhir SNS 2014
32 Next: Phase 2a study in mild AD Exploratory endpoint 6 mo rx Biomarkers: FDG-PET, MRI CSF p-tau/tau, Aβ, choline acetyltransferase activity Clinical measures: ADAS-Cog-14, NPI, Cogstate
What We Can Do To Prevent or Reduce the Risk for Dementia
What We Can Do To Prevent or Reduce the Risk for Dementia Colloquium on Health and Wellness October 10 th, 2018 Frank M. Longo, MD, PhD Professor and Chair Department of Neurology and Neurological Sciences
More informationSmall Molecule, Non-Peptide p75 NTR Ligands Inhibit Ab- Induced Neurodegeneration and Synaptic Impairment
Small Molecule, Non-Peptide p75 NTR Ligands Inhibit Ab- Induced Neurodegeneration and Synaptic Impairment Tao Yang 1,2., Juliet K. Knowles 1,2., Qun Lu 3, Hong Zhang 4, Ottavio Arancio 4, Laura A. Moore
More informationAn integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech
More informationTAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE
TAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE Benoît Melchior, C. Lai, K. Duong-Polk, A. Tjitro, D.C. Ince,
More informationHOMOTAURINE INVESTIGATIONAL SUMMARY
HOMOTAURINE INVESTIGATIONAL SUMMARY Amyloid Precursor Protein (brain) Amyloid Aß Amyloid fibril Amyloid plaque action mechanism Aisen PS. Presented at: 9th International Geneva Springfield Symposium on
More informationJ. Thomas Megerian, MD, PhD Executive Director, Clinical Research March 28, 2008
Results of a Phase 2A Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer s Disease J. Thomas Megerian, MD, PhD Executive Director, Clinical Research March 28, 2008 EPIX: GPCR Focused Drug Discovery
More informationNovel drug developed to treat type 2 diabetes are neuroprotective Alzheimer s disease
Novel drug developed to treat type 2 diabetes are neuroprotective Alzheimer s disease Prof. Christian Hölscher, PhD Biomed and Life Sciences Faculty of Health and Medicine Lancaster University, UK Alzheimer
More informationNNZ-2566 in Rett Syndrome and Autism Spectrum Disorders Role and Update
NNZ-2566 in Rett Syndrome and Autism Spectrum Disorders Role and Update 1 Overview The natural growth factor IGF-1 is broken down in the body to IGF-1[1-3] NNZ-2566 is an analogue of IGF-1[1-3] developed
More informationTAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE
TAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRKA INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE Benoît Melchior, Carolyn Lai, Karen Duong-Polk, Amanda Tjitro,
More informationSelective filtering defect at the axon initial segment in Alzheimer s disease mouse models. Yu Wu
Selective filtering defect at the axon initial segment in Alzheimer s disease mouse models Yu Wu Alzheimer s Disease (AD) Mouse models: APP/PS1, PS1δE9, APPswe, hps1 Wirths, O. et al, Acta neuropathologica
More informationThe Calpain / Calpastatin System in TBI and Chronic Neurodegeneration
The Calpain / Calpastatin System in TBI and Chronic Neurodegeneration Kathryn E. Saatman, Ph.D. Departments of Physiology and Neurosurgery Spinal Cord and Brain Injury Research Center Saatman lab: Dr.
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationPersistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment
Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment Bing Gong,, Michael Shelanski, Ottavio Arancio J Clin Invest. 2004;114(11):1624-1634. https://doi.org/10.1172/jci22831.
More informationWnt Signaling Pathway and AD
Center for Cell Regulation and Pathology Joaquín V. Luco (CRCP), Millennium Institute (MIFAB) Center for Aging and Regeneration (CARE). Wnt Signaling Pathway and AD Nibaldo C. Inestrosa European Union
More informationMecanismo de acción de Souvenaid: nuevos datos preclínicos
Mecanismo de acción de Souvenaid: nuevos datos preclínicos Dra. Sagrario Manzano Coordinadora del Grupo de Neurología de la Conducta y Demencias de la SEN. Hospital Universitario Infanta Cristina. Parla.
More informationTau Mechanism in Dementia
ADC Directors Meeting Saturday, April 12, 2008 Sheraton V Tau Mechanism in Dementia Lennart Mucke, M.D. Director, Gladstone Institute of Neurological Disease Joseph B. Martin Distinguished Professor Department
More informationNeuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide
Neuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide Bruce H. Morimoto, Ph.D. Executive Director, Applied Translational Medicine Microtubules Microtubules essential for neuronal
More informationChapter 11: Inherited Disorders of Human Memory Mental Retardation Syndromes. From Mechanisms of Memory, second edition By J. David Sweatt, Ph.D.
Chapter 11: Inherited Disorders of Human Memory Mental Retardation Syndromes From Mechanisms of Memory, second edition By J. David Sweatt, Ph.D. Chapter 11: Mental Retardation Syndromes Table I: Mouse
More informationNeuroinflammation in preclinical AD: in vivo evidence
Neuroinflammation in preclinical AD: in vivo evidence Barbara Bendlin, PhD Assistant Professor UW-Madison Dept. of Medicine, Geriatrics bbb@medicine.wisc.edu Overview Background Preclinical effects of
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationEarly Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.
Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods Christos Davatzikos, Ph.D. Director, Section of Biomedical Image Analysis Professor of Radiology http://www.rad.upenn.edu/sbia
More informationALZHEIMER S DISEASE FACTOIDS & STATISTICS
ALZHEIMER S DISEASE FACTOIDS & STATISTICS ~ 4 million affected in US alone 6-8% if 65+ years old, 30-50% if 80+ By 2030, in US >65 million people >65+ (---> ~14 million with AD) AD is one of the top 10
More informationILSI Europe Satellite Workshop on Nutrition for the Ageing Brain: Towards Evidence for an Optimal Diet
ILSI Europe Satellite Workshop on Nutrition for the Ageing Brain: Towards Evidence for an Optimal Diet 03-04 July 2014, Milan, Italy Nutritional effects on cognitive ageing Trial data Dr. Ir. Ondine van
More informationThe Opportunity: c-ibs and pain relief with confidence YKP10811
The Opportunity: c-ibs and pain relief with confidence YKP10811 1 TABLE OF CONTENTS Profile Summary Clinical Data Mode of Action Pharmacologic Profile Safety and Toxicity Profile ADME Overview vs. Competitors
More informationPROPOSAL: Translational Safety Biomarker Assessment of Neurotoxicity
PROPOSAL: Translational Safety Biomarker Assessment of Neurotoxicity Andreas Jeromin, PhD Chief Scientific Officer NextGen Sciences DX Boston, MA Emerging Issues Session HESI Annual Meeting 12 June 2012
More informationNutrition and Water for Dementia Prevention
台日生技醫藥研討會 - 自然療法於失智症預防及照護之應用 Nutrition and Water for Dementia Prevention 胡朝榮 Chaur-Jong Hu, M.D. Professor and Direction, Department of Neurology and Dementia Center, Shuang Ho Hospital, Taipei Medical
More informationResearch Development: Bedside to Bench and Back
Research Development: Bedside to Bench and Back Matt Bellizzi, MD PhD Department of Neurology University of Rochester School of Medicine and Dentistry Rochester, NY "I can walk down the hall just fine,
More informationThe Anti-Aβ Oligomer Drug CT1812 for Alzheimer s: Phase 1b/2a Safety Trial Outcomes
The Anti-Aβ Oligomer Drug CT1812 for Alzheimer s: Phase 1b/2a Safety Trial Outcomes Lon S Schneider, MD 1, Michael Grundman, MD, MPH 3,2, MS, Steven DeKosky, MD 4, Roger Morgan, MD 5, Robert Guttendorf
More informationmtorc2 controls actin polymerization required for consolidation of long-term memory
CORRECTION NOTICE Nat. Neurosci.; doi:1.138/nn.3351 mtorc2 controls actin polymerization required for consolidation of long-term memory Wei Huang, Ping Jun Zhu, Shixing Zhang, Hongyi Zhou, Loredana Stoica,
More informationDietary Flavonoids: Modulators of Brain Ageing?
MLECULAR NUTRITIN GRUP Established 2004 Dietary Flavonoids: Modulators of Brain Ageing? Jeremy P E Spencer School of Food Biosciences University of Reading, UK The Sensitivity of the Brain to xidative
More informationSafety, Tolerability and Target Engagement Demonstrated in Phase 1 Study of LRRK2 Inhibitor DNL201 in Healthy Young and Elderly Adults
Safety, Tolerability and Target Engagement Demonstrated in Phase 1 Study of LRRK2 Inhibitor DNL201 in Healthy Young and Elderly Adults MJFF Parkinson s Disease Therapeutics Conference October 25, 2018
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationPT/MR evaluation of athletes with postconcussion syndrome
PT/MR evaluation of athletes with postconcussion syndrome Niklas Marklund Professor@Dept. of Clinical Sciences Lund, Neurosurgery, Lund University, Sweden Sports-related concussions- basic facts Recovery
More informationStrategies for Neurorestoration: Growth Factors
Strategies for Neurorestoration: Growth Factors Elena Posse de Chaves, PhD 928-MSB Phone: 492-5966 Email: elena.chaves@ualberta.ca Treatment of Neurodegenerative Diseases Most neurodegenerative diseases
More informationCellular Mechanisms of Learning and the Biological Basis of Individuality
The Study of Memory Has Two Parts: Cellular Mechanisms of Learning and the Biological Basis of Individuality (1) The Systems Problem of Memory: Where in the brain is memory stored? (2) The Molecular Problem
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationALM301: Allosteric Isoform selective Akt inhibitor
ALM301: Allosteric Isoform selective Akt inhibitor Background Akt1/2 selective inhibitors ALM301 Back-up compounds Akt2 selective inhibitors Approaches to Akt Inhibition Both ATP competitive and allosteric
More informationStatins and Cognition A Focus on Mechanisms
Statins and Cognition A Focus on Mechanisms Note: Deleted copyrighted graphs/tables are described In red text and source references are provided Disclosures: SPARCL Steering Committee and past consultant
More informationThe effect of diets on neurodegenerative diseases
The effect of diets on neurodegenerative diseases Results from the FP7 project LIPIDIDIET A Kiliaan Donders Institute for Brain, Cognition and Behaviour, Centre for Neuroscience Dept Anatomy and dept Cognitive
More informationNature Neuroscience: doi: /nn Supplementary Figure 1. Large-scale calcium imaging in vivo.
Supplementary Figure 1 Large-scale calcium imaging in vivo. (a) Schematic illustration of the in vivo camera imaging set-up for large-scale calcium imaging. (b) High-magnification two-photon image from
More informationTGF-ß1 pathway as a new pharmacological target for neuroprotection in AD. Filippo Caraci
Department of Clinical and Molecular Biomedicine Section of Pharmacology and Biochemistry Department of Educational Sciences University of Catania TGF-ß1 pathway as a new pharmacological target for neuroprotection
More informationTherapeutic Strategies for Cognitive Dysfunction in People with Down Syndrome
Therapeutic Strategies for Cognitive Dysfunction in People with Down Syndrome Ahmad Salehi, M.D., Ph.D VA Palo Alto Health Care System & Department of Psychiatry & Behavioral Sciences, Stanford Medical
More informationAlzheimer's Disease A mind in darkness awaiting the drink of a gentle color.
Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Gabriel García Márquez One Hundred Years of Solitude Alois Alzheimer
More informationPrimary Mouse Cerebral Cortex Neurons V: 80% TE: 70%
Primary Mouse Cerebral Cortex Neurons V: 80% TE: 70% Pictures: 9 days after electroporation Red: MAP2 Blue: GFAP Green: GFP The cells were from Embryonic Day 14 Mouse Cerebral Cortex Primary Mouse Hippocampal
More informationAdvances in the Role of ADF / Cofilin in Central Nervous System
Advances in Engineering Research (AER), volume 124 2nd International Symposium on Advances in Electrical, Electronics and Computer Engineering (ISAEECE 2017) Advances in the Role of ADF / Cofilin in Central
More informationSharon Shacham, Ph.D. ICAD, July 29th, 2008 NASDAQ: EPIX
Stimulation of Serotonin Type 4 Receptors Leads to Increases in Alpha-Secreatase Activity and sappalpha: Potential for Disease Modification in Alzheimer's Disease Sharon Shacham, Ph.D. ICAD, July 29th,
More informationEmerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018
Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as
More informationSUPPLEMENTARY INFORMATION
Supplementary Figure 1. Normal AMPAR-mediated fepsp input-output curve in CA3-Psen cdko mice. Input-output curves, which are plotted initial slopes of the evoked fepsp as function of the amplitude of the
More informationSUPPLEMENTARY INFORMATION
Supplementary Figure 1. Behavioural effects of ketamine in non-stressed and stressed mice. Naive C57BL/6 adult male mice (n=10/group) were given a single dose of saline vehicle or ketamine (3.0 mg/kg,
More informationSleep and Circadian Rhythms in Neurodegenerative Disorders
Sleep and Circadian Rhythms in Neurodegenerative Disorders Erik S. Musiek, MD, PhD Department of Neurology Washington University in St. Louis U13 Bench to Bedside Sleep Conference 2015 Disclosures Funding:
More information9.01 Introduction to Neuroscience Fall 2007
MIT OpenCourseWare http://ocw.mit.edu 9.01 Introduction to Neuroscience Fall 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. 9.01 Recitation (R02)
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationIssues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital
Project to Promote the Development of Innovative Pharmaceuticals, Medical Devices, and Regenerative Medical Products (Ministry of Health, Labour, and Welfare) Regulatory Science Research for the Establishment
More informationCharlie Taylor, PhD CpTaylor Consulting Chelsea, MI, USA
Contribution of Calcium Channel α 2 δ Binding Sites to the Pharmacology of Gabapentin and Pregabalin Charlie Taylor, PhD CpTaylor Consulting Chelsea, MI, USA Disclosure Information Charlie Taylor, PhD
More informationSUPPLEMENTARY INFORMATION
doi: 10.1038/nature05772 SUPPLEMENTARY INFORMATION Supplemental figure 1. Enrichment facilitates learning. a. Images showing a home cage and a cage used for environmental enrichment (EE). For EE up to
More informationThe Carroll A. Campbell, Jr. Neuropathology Laboratory: A Tool for Dementia Discovery in South Carolina
The Carroll A. Campbell, Jr. Neuropathology Laboratory: A Tool for Dementia Discovery in South Carolina Pathology in the Cerebral Cortex H&E stain of mature neuritic plaque Modified Bielschowsky stain
More informationSUPPLEMENTARY INFORMATION
DOI: 10.1038/ncb2566 Figure S1 CDKL5 protein expression pattern and localization in mouse brain. (a) Multiple-tissue western blot from a postnatal day (P) 21 mouse probed with an antibody against CDKL5.
More informationPositron Emission Tomography of Translocator Protein 18 kda (TSPO) as a Biomarker of Neuroinflammation in Dementia and in Depression
Positron Emission Tomography of Translocator Protein 18 kda (TSPO) as a Biomarker of Neuroinflammation in Dementia and in Depression Robert B. Innis, MD, PhD Chief, Molecular Imaging Branch NIMH Translocator
More informationRoche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex
More informationSupplementary Figure 1. Western blot of hippocampal lysates from WT and Adcy1 KO mice demonstrates the specificity of the ADCY1 antibody.
ADCY1 13 kda β-actin 45 kda Supplementary Figure 1. Western blot of hippocampal lysates from and mice demonstrates the specificity of the ADCY1 antibody. a DHPG perk1/2 ERK1/2 Relative level min 1.6 *
More informationSupplementary Fig. 1
PDK1-dependent quenching of TACE shedding activity in prion and Alzheimer s diseases Mathéa Pietri, Caroline Dakowski, Samia Hannaoui, Aurélie Alleaume-Butaux, Julia Hernandez-Rapp, Audrey Ragagnin, Sophie
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationRational Drug Used For Cognitive Treatment of Alzheimer Disease And Related Dementia
Spectrum of AD Rational Drug Used For Cognitive Treatment of Alzheimer Disease And Related Dementia Assoc.Prof. Vorapun Senanarong, BSc., MD., DTM&H(London), FRCP(London) MCI, mild cognitive Impairment
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationFinal Scientific Progress Report
CUREPSP Final Scientific Progress Report Tau in Peripheral Tissues of PSP and CBD. Brittany Dugger, PhD; University of California San Francisco Specific Aim: Using immunohistochemical methods on autopsy
More informationHerpes Simplex Virus Type 1 and Alzheimer s disease:
The Neurodegenerates Herpes Simplex Virus Type 1 and Alzheimer s disease: Increasing Evidence for a major role of the virus 1 Introduction and Agenda 2 Agenda What is the HSV1 and why is it linked to AD?
More informationTammie Benzinger, MD, PhD
Tammie Benzinger, MD, PhD benzingert@wustl.edu Disclosure: Tammie L.S. Benzinger, M.D., Ph.D. Research Support / Grants: NIH/NIA 5P01AG026276, 1U01AG032438, AG003991-27, 1R01NS066905-01, 1P01NS059560-01A1,
More informationSupplementary Materials for
www.sciencesignaling.org/cgi/content/full/7/308/ra4/dc1 Supplementary Materials for Antipsychotics Activate mtorc1-dependent Translation to Enhance Neuronal Morphological Complexity Heather Bowling, Guoan
More informationAT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE
AT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology Mary Quiceno, MD discloses she has received honoraria
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationAdvances in Alzheimer s diagnosis; implications for clinical practice. Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017
Advances in Alzheimer s diagnosis; implications for clinical practice Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017 Grand Challenge Alzheimer s disease 47 million worldwide
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationDelta-Secretase Phosphorylation by SRPK2 Enhances Its Enzymatic Activity, Provoking Pathogenesis in Alzheimer s Disease
Article Delta-Secretase Phosphorylation by SRPK2 Enhances Its Enzymatic Activity, Provoking Pathogenesis in Alzheimer s Disease Graphical Abstract Authors Zhi-Hao Wang, Pai Liu, Xia Liu,..., Shan Ping
More informationNew Approach to Parkinson s Disease: Synuclein Immunotherapy
RB2014 Conference August 22, 2014 New Approach to Parkinson s Disease: Synuclein Immunotherapy Dale Schenk, PhD President and CEO Prothena Corporation plc Primary Motor and Non-Motor Symptoms of Parkinson
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationMolecular Mechanisms of Environmental Enrichment: Impairments in Akt/GSK3b, Neurotrophin-3 and CREB Signaling
Molecular Mechanisms of Environmental Enrichment: Impairments in Akt/GSK3b, Neurotrophin-3 and CREB Signaling Yuan-Shih Hu, Nancy Long, Gustavo Pigino, Scott T. Brady, Orly Lazarov* Department of Anatomy
More informationMary ET Boyle, Ph. D. Department of Cognitive Science UCSD
? Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Christian S Lobsiger & Don W Cleveland (2007) Nature Neuroscience 10, 1355-1360 Astrocytes: interlinked gatekeepers of glutamate astrocytes
More informationTOWARD EFFECTIVE ALZHEIMER S THERAPY: PROGRESS AND COLLABORATION. Paul S. Aisen, MD Department of Neurosciences University of California, San Diego
TOWARD EFFECTIVE ALZHEIMER S THERAPY: PROGRESS AND COLLABORATION Paul S. Aisen, MD Department of Neurosciences University of California, San Diego Brief History of AD Therapeutics 1906: Dr. Alois Alzheimer
More informationILSI Europe Satellite Workshop on Nutrition for the Ageing Brain: Towards Evidence for an Optimal Diet July 2014, Milan, Italy
ILSI Europe Satellite Workshop on Nutrition for the Ageing Brain: Towards Evidence for an Optimal Diet 03-04 July 2014, Milan, Italy Flavonoids as modulators of APP Processing: A Dietary intervention for
More informationNeuronal Plasticity, Learning and Memory. David Keays Institute of Molecular Pathology
Neuronal Plasticity, Learning and Memory David Keays Institute of Molecular Pathology http://keayslab.org Structure 1. What is learning and memory? 2. Anatomical basis 3. Cellular basis 4. Molecular
More informationSupplementary Materials for. c-abl Activation Plays a Role in α-synucleinopathy Induced Neurodegeneration
Supplementary Materials for c-abl Activation Plays a Role in α-synucleinopathy Induced Neurodegeneration Saurav Brahmachari, Preston Ge, Su Hyun Lee, Donghoon Kim, Senthilkumar S. Karuppagounder, Manoj
More informationTropisetron: A promising drug to prevent Alzheimer s disease
Expert Opinion on Therapeutic Targets (Editorial) Tropisetron: A promising drug to prevent Alzheimer s disease Short title: Tropisetron for Alzheimer s disease Word count of the manuscript: 1324 words
More informationMicroglia, Inflammation, and FTD
FTD Minicourse April, 2009 Microglia, Inflammation, and FTD Li Gan, Ph.D Gladstone Institute of Neurological Disease University of California, San Francisco Outline Why study inflammation in neurodegeneration?
More informationAlzheimer s Disease: the Discovery of a Novel Phosphodiesterase 5 Inhibitor for its Cure.
Alzheimer s Disease: the Discovery of a ovel Phosphodiesterase 5 Inhibitor for its Cure. Jole Fiorito, Ph.D. U.S. Pat. Appl. Publ. (2012), US 20120076732 A1 20120329. I thought elephants never forgot,
More informationCASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories?
CASE 49 A 43-year-old woman is brought to her primary care physician by her family because of concerns about her forgetfulness. The patient has a history of Down syndrome but no other medical problems.
More informationSynaptic plasticityhippocampus. Neur 8790 Topics in Neuroscience: Neuroplasticity. Outline. Synaptic plasticity hypothesis
Synaptic plasticityhippocampus Neur 8790 Topics in Neuroscience: Neuroplasticity Outline Synaptic plasticity hypothesis Long term potentiation in the hippocampus How it s measured What it looks like Mechanisms
More informationAlzheimer s disease. The future of clinical trials: big problem, Big Data, big solution?
Alzheimer s disease The future of clinical trials: big problem, Big Data, big solution? The Problem More than 36m people with dementia Consumes 1% global GDP Serial trials failure Targets for therapy Nothing
More informationAddressing nutritional requirements in early
Addressing nutritional requirements in early Alzheimer s disease: what, why and when? Laus Broersen, PhD Senior Neuroscientist Nutricia Research, Advanced Medical Nutrition Utrecht, The Netherlands AD
More information9.01 Introduction to Neuroscience Fall 2007
MIT OpenCourseWare http://ocw.mit.edu 9.01 Introduction to Neuroscience Fall 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. Working memory short-term
More informationThe Opportunity: Parkinson s disease, RLS, ADHD, and disease modification YKP10461
The Opportunity: Parkinson s disease, RLS, ADHD, and disease modification YKP10461 1 TABLE OF CONTENTS Profile Summary Mechanism of Action Clinical Study Results Pharmacologic Profile Safety and Toxicity
More informationCognitive Enhancement Strategies. Florian Plattner, James A. Bibb
Cognitive Enhancement Strategies Florian Plattner, James A. Bibb A decline in memory and cognitive function is a natural aspect of aging. In addition, cognitive deficits are comorbid with many mental disorders
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More informationDisclosures. Advisor to: Alopexx Enterprises, LLC CannScience Cognoptix, Inc. IntelGenx KalGene Neurodyn Treventis Corp.
Drug Repurposing for Use in the AD Population - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - considerations and limitations Barry D. Greenberg, Ph.D. Director,
More informationTargeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor
Targeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor Josep Tabernero, Andrés Cervantes, Cristina Saura, Desamparados Roda, Yibing Yan, Kui Lin, Sumati Murli,
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationClaims & Underwriting. You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association
Claims & Underwriting Alzheimer s & Cognitive Impairment: You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association 1 OVERVIEW Impact
More informationINI. Therapeutic Effects of Intranasally-Administered Insulin (INI) for amci or Mild AD. Study of Nasal Insulin to Fight Forgetfulness (AKA)
INI Training Meeting Nov 5 th 2013, San Diego INI Therapeutic Effects of Intranasally-Administered Insulin (INI) for amci or Mild AD (AKA) Study of Nasal Insulin to Fight Forgetfulness Project Director
More informationNovember 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Treatment Targets in Alzheimer s Disease W. Vaughn McCall, MD, MS Professor and Case Distinguished University Chairman Department of Psychiatry
More informationMolecular Imaging Heterogeneity of Clinically Defined AD
Molecular Imaging Heterogeneity of Clinically Defined AD Gil Rabinovici, M.D. Edward Fein & Pearl Landrith Endowed Professor UCSF Memory & Aging Center 2017 Spring ADC Meeting Boston, MA April 22, 2017
More information